Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2017 Mar 17

PMID 28299346

Citations 10

Authors

Dilyara Akberova

Andrei P Kiassov

Diana Abdulganieva

Affiliations

Soon will be listed here.

Abstract

Serum cytokine levels were explored in a combined group of patients with autoimmune liver diseases (AILDs) and separately in patients with autoimmune hepatitis (AIH) and overlap syndrome. Overall, 60 patients with AILD, among them 32 patients with AIH and 28 patients with overlap syndrome, were included in the cross-sectional study. Serum cytokine levels were measured at baseline and compared to those of 21 healthy controls. Patients with AILD had significantly higher levels of IL-6 (0.70 (range 0.17-99.86) in patients with AILD compared to 0.40 (range 0.14-2.65) in controls, < 0.01), IL-8 (1.66 (0.45-34.58) versus 0.53 (0.35-2.38), resp., < 0.01), and TNF- (2.61 (0.23-120.88) versus 1.65 (0.21-7.54), resp., < 0.01). Adjusted logistic regression analysis revealed a pronounced relation of IL-8 and AILD, 48.36 (3.63-643.60), as well as AIH, 18.54 (1.08-318.54), and overlap syndrome, 23.85 (2.37-240.23), while the associations between the level of other cytokines and AILD were assessed as nonsignificant. In the language of absolute numbers, the increase of IL-8 serum level by 1 pg/mL had increased the chance for a patient to find himself in a group of AILD by 48.36 times. Also, high IL-8 serum levels were strongly related to clinical parameters.

Citing Articles

Multi-omics approaches for drug-response characterization in primary biliary cholangitis and autoimmune hepatitis variant syndrome.

Yang F, Zhou L, Shen Y, Wang X, Fan X, Yang L J Transl Med. 2024; 22(1):214.

PMID: 38424613 PMC: 10902991. DOI: 10.1186/s12967-024-05029-6.

β-arrestin2 deficiency ameliorates S-100-induced autoimmune hepatitis in mice by inhibiting infiltration of monocyte-derived macrophage and attenuating hepatocyte apoptosis.

Chen T, Li X, Li N, Xu Y, Wang Y, Wang Z Acta Pharmacol Sin. 2023; 44(10):2048-2064.

PMID: 37225848 PMC: 10545685. DOI: 10.1038/s41401-023-01103-9.

Deng C, Yang M, Jiang H, Wang R, Yang Z, Sun H Front Oncol. 2021; 11:664809.

PMID: 34540659 PMC: 8443792. DOI: 10.3389/fonc.2021.664809.

Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.

Liu Y, Zhang J, Yin Z, Zhu X, Xue L, Cao B Thorac Cancer. 2020; 11(7):2023-2030.

PMID: 32379397 PMC: 7327908. DOI: 10.1111/1759-7714.13463.

Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma-An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer.

Wahl R, Leijs M, Araujo A, Rubben A Int J Mol Sci. 2020; 21(6).

PMID: 32188047 PMC: 7139313. DOI: 10.3390/ijms21062020.

References

Dirchwolf M, Podhorzer A, Marino M, Shulman C, Cartier M, Zunino M . Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2015; 77:14-25. DOI: 10.1016/j.cyto.2015.10.006. View

Montano-Loza A, Czaja A . Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci. 2014; 60(6):1528-42. DOI: 10.1007/s10620-014-3473-z. View

Longhi M, Ma Y, Mieli-Vergani G, Vergani D . Adaptive immunity in autoimmune hepatitis. Dig Dis. 2010; 28(1):63-9. DOI: 10.1159/000282066. View

Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X . Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011; 6(4):e18909. PMC: 3079758. DOI: 10.1371/journal.pone.0018909. View

Al-Chalabi T, Portmann B, Bernal W, McFarlane I, Heneghan M . Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther. 2008; 28(2):209-20. DOI: 10.1111/j.1365-2036.2008.03722.x. View

Manns M, Czaja A, Gorham J, Krawitt E, Mieli-Vergani G, Vergani D . Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51(6):2193-213. DOI: 10.1002/hep.23584. View

Jepsen P, Gronbaek L, Vilstrup H . Worldwide Incidence of Autoimmune Liver Disease. Dig Dis. 2015; 33 Suppl 2:2-12. DOI: 10.1159/000440705. View

Bo X, Broome U, Remberger M, Sumitran-Holgersson S . Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut. 2001; 49(1):131-41. PMC: 1728361. DOI: 10.1136/gut.49.1.131. View

Baier J, Mattner J . Mechanisms of autoimmune liver disease. Discov Med. 2014; 18(100):255-63. View

10.

. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2):237-67. DOI: 10.1016/j.jhep.2009.04.009. View

11.

Ding C, Cicuttini F, Li J, Jones G . Targeting IL-6 in the treatment of inflammatory and autoimmune diseases. Expert Opin Investig Drugs. 2009; 18(10):1457-66. DOI: 10.1517/13543780903203789. View

12.

Boberg K, Chapman R, Hirschfield G, Lohse A, Manns M, Schrumpf E . Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2010; 54(2):374-85. DOI: 10.1016/j.jhep.2010.09.002. View

13.

Zimmermann H, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C . Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One. 2011; 6(6):e21381. PMC: 3120868. DOI: 10.1371/journal.pone.0021381. View

14.

Feld J, Heathcote E . Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol. 2003; 18(10):1118-28. DOI: 10.1046/j.1440-1746.2003.03165.x. View

15.

Maggiore G, De Benedetti F, Massa M, Pignatti P, Martini A . Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 1995; 20(1):23-7. DOI: 10.1097/00005176-199501000-00005. View

16.

Liberal R, Grant C . Cirrhosis and autoimmune liver disease: Current understanding. World J Hepatol. 2016; 8(28):1157-1168. PMC: 5055585. DOI: 10.4254/wjh.v8.i28.1157. View

17.

Trivedi P, Hirschfield G . Treatment of autoimmune liver disease: current and future therapeutic options. Ther Adv Chronic Dis. 2013; 4(3):119-41. PMC: 3629750. DOI: 10.1177/2040622313478646. View

18.

Bunchorntavakul C, Reddy K . Diagnosis and management of overlap syndromes. Clin Liver Dis. 2014; 19(1):81-97. DOI: 10.1016/j.cld.2014.09.005. View

19.

Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I . Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun. 2009; 33(3-4):178-82. DOI: 10.1016/j.jaut.2009.09.010. View

20.

Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R . Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol. 2006; 169(6):2042-53. PMC: 1762467. DOI: 10.2353/ajpath.2006.060081. View